Should I Buy KNSA? KNSA 2026 Analysis

Should You Buy Kiniksa Pharmaceuticals International PLC (KNSA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

43.090

1 Day change

1.20%

52 Week Range

45.500

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient buyer: there is no proprietary buy signal, the near-term statistical drift is slightly negative, and price is sitting right on a key pivot where follow-through is uncertain.
Upside exists if it reclaims and holds above ~~45.10 (R1), but at the current pre-market level (~~43.1) the setup is more “wait/hold” than “must-buy.”

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend/structure: Bullish moving-average stack (SMA_5 > SMA_20 > SMA_200) suggests the broader trend is up.
Momentum: MACD histogram +0.271 and contracting → bullish momentum is still positive but losing strength.
RSI: RSI(6) ~51.2 (neutral) → no oversold “snap-back” edge and no overbought pressure either.
Key levels: Pivot 43.466 (price is hovering around this area pre-market). Support 41.831 (S1) then 40.821 (S2). Resistance 45.101 (R1) then 46.111 (R2).
Practical read: bullish longer trend, but near-term entry is not clean unless price either (a) dips closer to S1/S2 with stabilization or (b) breaks and holds above R1.

Options Data

Bullish

Open Interest Put-Call Ratio

Neutral

Option Volume Put-Call Ratio

Positioning: Open Interest Put/Call = 0.03 (puts are tiny vs calls) → options positioning skews bullish, but may also reflect limited put hedging rather than fresh bullish conviction.
Activity: today’s volume is very low (2 contracts), even though volume vs 30D average is elevated (low base effect). This limits how much sentiment you can infer from today’s tape.
Volatility: IV 30D ~60.44% vs historical vol ~41.91% → options look rich/expensive, suggesting the market is pricing meaningful moves or uncertainty.
IV rank/percentile: IV Rank ~16.35 / IV Percentile ~41.83 → not at an extreme, but still elevated versus realized volatility.

Technical Summary

Sell

Buy

Positive Catalysts

- Broader technical backdrop remains constructive (bullish MA alignment), which can support dips getting bought.
- Options open interest is heavily call-skewed (very low put/call OI), consistent with a market leaning bullish.
- Strong top-line growth in the latest reported quarter (2025/Q3 revenue +61% YoY).

Neutral/Negative Catalysts

- No Intellectia buy signals (AI Stock Picker and SwingMax both absent) → no high-conviction timing edge today.
- Near-term pattern-based outlook provided is slightly negative: ~50% chance of -0.32% next day, -1.3% next week, -0.9% next month.
- Momentum is fading (MACD positive but contracting), raising the risk of chop or pullback around the pivot.
- No recent news catalysts in the past week to drive a clean breakout.

Financial Performance

Latest quarter provided: 2025/Q3.
Revenue: $180.855M, +61.17% YoY (strong growth).
Profitability: Net income $18.435M, down -245.24% YoY and EPS $0.23, down -227.78% YoY → earnings deteriorated sharply despite revenue growth.
Margins: Gross margin 88.8% (+8.19% YoY) → underlying gross profitability improved, implying the EPS pressure is likely from opex/other items rather than gross margin compression.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price-target change data was provided in the dataset, so there’s no confirmed recent trend to summarize.
Wall Street-style bull case (based on provided fundamentals): strong revenue growth and very high gross margins support longer-term upside.
Wall Street-style bear case: sharp YoY decline in net income/EPS raises questions about expense trajectory and earnings quality; without fresh catalysts, upside may be slower and more volatile.

Politicians/influential figures: no recent congress trading data available (last 90 days) and no reported notable political/influential trading in the provided data.

6 Analyst Rating

Wall Street analysts forecast KNSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KNSA is 53.5 USD with a low forecast of 48 USD and a high forecast of 60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 42.580

Low

Averages

53.5

High

Current: 42.580

Low

Averages

53.5

High

Goldman Sachs

Buy

upgrade

$45 -> $55

AI Analysis

2025-10-29

Reason

Goldman Sachs

Price Target

$45 -> $55

AI Analysis

2025-10-29

upgrade

Buy

Reason

Goldman Sachs raised the firm's price target on Kiniksa to $55 from $45 and keeps a Buy rating on the shares.

Citi

Geoff Meacham

Buy

maintain

$45 -> $50

2025-10-17

Reason

Citi

Geoff Meacham

Price Target

$45 -> $50

2025-10-17

maintain

Buy

Reason

Citi analyst Geoff Meacham raised the firm's price target on Kiniksa to $50 from $45 and keeps a Buy rating on the shares as part of a Q3 preview for the biotechnology group. The firm believes investor interest in the smaller cap biotech names is building, which could set the group up well for 2026.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KNSA

Unlock Now

KNSA Should I Buy

KNSA Should I Buy

Should You Buy Kiniksa Pharmaceuticals International PLC (KNSA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch